Small Molecule Inhibitors and Inflammatory Skin Diseases

    March 2018 in “ Suez Canal University Medical Journal ”
    Hanan Omar
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
    Inflammatory skin diseases (ISDs) were linked to the production of disease-relevant cytokines via the JAK-STAT pathway, which was crucial for various cytokines and growth factors. Targeting this pathway gained significant attention, leading to the development of new drugs to inhibit JAK and STAT molecules. Although only a few JAK inhibitors were FDA approved, others were in development. Notably, oral JAK1/JAK2 inhibitors like ruxolitinib and baricitinib induced hair regrowth in Alopecia areata patients, and the JAK1/JAK3 inhibitor tofacitinib showed significant improvement in psoriasis. This approach offered an alternative to neutralizing single cytokines with antibodies.
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results